Hypomethylating agents, such as azacytidine and decitabine, have demonstrated efficacy in treating individuals with TET2-mutant myeloid malignancies and warrant investigation for their potential to prevent AF in patients with CHIP. The gene discussed is STUB1; the disease is atrial fibrillation.